oru.sePublications
Change search
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf
Docetaxel does not impair skeletal muscle force production in a murine model of cancer chemotherapy
Örebro University, School of Health Sciences. Department of Physiology and Pharmacology, Karolinska Institutet, Stockholm, Sweden.ORCID iD: 0000-0002-5322-4150
Department of Physiology and Pharmacology, Karolinska Institutet, Stockholm, Sweden.
Department of Physiology and Pharmacology, Karolinska Institutet, Stockholm, Sweden.
2017 (English)In: Physiological Reports, E-ISSN 2051-817X, Vol. 5, no 11, article id e13261Article in journal (Refereed) Published
Abstract [en]

Chemotherapy drugs such as docetaxel are commonly used to treat cancer. Cancer patients treated with chemotherapy experience decreased physical fitness, muscle weakness and fatigue. To date, it is unclear whether these symptoms result only from cancer-derived factors or from the combination of cancer disease and cancer treatments, such as chemotherapy. In this study, we aimed at determining the impact of chemotherapy per se on force production of hind limb muscles from healthy mice treated with docetaxel. We hypothesized that docetaxel will decrease maximal force, exacerbate the force decline during repeated contractions and impair recovery after fatiguing stimulations. We examined the function of soleus and extensor digitorum longus (EDL) muscles 24h and 72h after a single injection of docetaxel (acute treatment), and 7days after the third weekly injection of docetaxel (repeated treatment). Docetaxel was administrated by intravenous injection (20mg/kg) in female FVB/NRj mice and control mice were injected with saline solution. Our results show that neither acute nor repeated docetaxel treatment significantly alters force production during maximal contractions, repeated contractions or recovery. Only a tendency to decreased peak specific force was observed in soleus muscles 24h after a single injection of docetaxel (-17%, P=0.13). In conclusion, docetaxel administered intravenously does not impair force production in hind limb muscles from healthy mice. It remains to be clarified whether docetaxel, or other chemotherapy drugs, affect muscle function in subjects with cancer and whether the side effects associated with chemotherapy (neurotoxicity, central fatigue, decreased physical activity, etc.) are responsible for the experienced muscle weakness and fatigue.

Place, publisher, year, edition, pages
American Physiological Society , 2017. Vol. 5, no 11, article id e13261
Keywords [en]
Acute and repeated treatments, disease, fatigue, muscle weakness, recovery
National Category
Physiology
Identifiers
URN: urn:nbn:se:oru:diva-58956DOI: 10.14814/phy2.13261ISI: 000403500600003PubMedID: 28583990Scopus ID: 2-s2.0-85020790483OAI: oai:DiVA.org:oru-58956DiVA, id: diva2:1134314
Funder
Swedish Research CouncilMagnus Bergvall FoundationWenner-Gren FoundationsAvailable from: 2017-08-18 Created: 2017-08-18 Last updated: 2018-01-13Bibliographically approved

Open Access in DiVA

No full text in DiVA

Other links

Publisher's full textPubMedScopus

Authority records BETA

Chaillou, Thomas

Search in DiVA

By author/editor
Chaillou, Thomas
By organisation
School of Health Sciences
In the same journal
Physiological Reports
Physiology

Search outside of DiVA

GoogleGoogle Scholar

doi
pubmed
urn-nbn

Altmetric score

doi
pubmed
urn-nbn
Total: 97 hits
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf